Angelman Syndrome

Mendelian MONDO:0007113 Pathograph 21 Neurodevelopmental disorder Imprinting disorder

Angelman syndrome is a neurogenetic imprinting disorder caused by deficient neuronal expression of the maternally inherited UBE3A allele, with severe developmental impairment, minimal speech, gait ataxia, seizures, and a characteristic behavioral phenotype.

0
Mappings
2
Definitions
1
Inheritance
8
Pathophysiology
0
Histopathology
12
Phenotypes
21
Pathograph
2
Genes
7
Treatments
4
Subtypes
3
Differentials
5
Datasets
3
Trials
0
Models
🏷

Classifications

Harrison's Chapter
hereditary disease nervous system disorder
📘

Definitions

2
Clinical syndrome definition
Angelman syndrome is defined clinically by severe developmental delay or intellectual disability, severe speech impairment, ataxic movement disorder, characteristic happy demeanor, and frequent co-occurrence of seizures and microcephaly.
CASE_DEFINITION Core clinical phenotype in pediatric and adult practice
Show evidence (2 references)
PMID:20301323 SUPPORT Human Clinical
"Angelman syndrome (AS) is characterized by severe developmental delay or intellectual disability, severe speech impairment, gait ataxia and/or tremulousness of the limbs, and unique behavior with an apparent happy demeanor that includes frequent laughing, smiling, and excitability."
Defines the canonical clinical syndrome.
PMID:20301323 SUPPORT Human Clinical
"Microcephaly and seizures are also common."
Adds core neurologic features used in clinical recognition.
Molecular diagnostic criteria framework
Molecular diagnosis is primarily established by 15q11.2-q13 methylation testing with reflex UBE3A sequence analysis when methylation testing is negative.
DIAGNOSTIC_CRITERIA Molecular confirmation strategy for suspected Angelman syndrome
Show evidence (2 references)
PMID:20301323 SUPPORT Human Clinical
"Analysis of parent-specific DNA methylation imprints in the 15q11.2-q13 chromosome region detects approximately 80% of individuals with AS, including those with a deletion, uniparental disomy, or an imprinting defect; fewer than 1% of individuals have a cytogenetically visible chromosome..."
Supports methylation analysis as first-line molecular testing.
PMID:20301323 SUPPORT Human Clinical
"UBE3A sequence analysis detects pathogenic variants in an additional approximately 11% of individuals."
Supports second-tier sequencing for methylation-negative cases.
👪

Inheritance

1
Autosomal dominant inheritance with maternal imprinting HP:0012275
Disease expression requires loss of the maternally inherited functional UBE3A allele in neurons; most cases are simplex/de novo.
Autosomal dominant inheritance with maternal imprinting Penetrance: COMPLETE
Show evidence (2 references)
PMID:20301323 SUPPORT Human Clinical
"Individuals with AS typically represent simplex cases (i.e., a single affected family member) and have the disorder as the result of a de novo genetic alteration associated with a very low recurrence risk."
Supports predominant de novo occurrence in clinical practice.
PMID:20301323 SUPPORT Human Clinical
"Less commonly, an individual with AS has the disorder as the result of a genetic alteration associated with an imprinting pattern of autosomal dominant inheritance or variable recurrence risk."
Supports the imprinting-associated autosomal dominant inheritance mechanism.
◆

Subtypes

4
Maternal 15q11.2-q13 deletion Angelman syndrome
70%
Most common molecular subtype, caused by de novo deletion of the maternally inherited 15q11.2-q13 region including UBE3A.
Show evidence (1 reference)
PMID:14510623 SUPPORT Human Clinical
"Approximately 70% of patients show a deletion involving the maternally inherited chromosome 15q11-q13, encompassing a cluster of gamma-aminobutyric acid receptor subunit genes"
Quantifies and defines the major deletion subtype.
UBE3A pathogenic variant Angelman syndrome
6-11% UBE3A
Subtype caused by pathogenic variants in maternally inherited UBE3A.
Show evidence (2 references)
PMID:14510623 SUPPORT Human Clinical
"6% harbor intragenic mutations of the ubiquitin-protein ligase E3A (UBE3A) gene."
Supports a distinct UBE3A-variant molecular subtype.
PMID:20301323 SUPPORT Human Clinical
"UBE3A sequence analysis detects pathogenic variants in an additional approximately 11% of individuals."
Provides an additional estimate from a contemporary GeneReviews summary.
Paternal uniparental disomy 15 Angelman syndrome
3%
Subtype caused by paternal uniparental disomy of chromosome 15 with absent functional maternal UBE3A contribution in neurons.
Show evidence (1 reference)
PMID:14510623 SUPPORT Human Clinical
"3% show chromosome 15 paternal uniparental disomy (UPD)"
Supports UPD as a recognized molecular subtype.
Imprinting defect Angelman syndrome
1%
Subtype caused by imprinting center defects disrupting maternal-expression pattern at the 15q11.2-q13 locus.
Show evidence (1 reference)
PMID:14510623 SUPPORT Human Clinical
"1% harbor a mutation in the imprinting center (a transcriptional regulatory element)"
Supports imprinting-center defects as a rarer molecular subtype.
⚙

Pathophysiology

8
Maternal UBE3A allele disruption
Angelman syndrome is initiated by disruption of the maternally inherited UBE3A allele (deletion, pathogenic variant, UPD context, or imprinting defect).
neuron link
UBE3A link
nervous system link
Show evidence (1 reference)
PMID:33543479 SUPPORT Other
"Angelman syndrome is caused by mutations affecting the maternally inherited UBE3A gene, which encodes an E3-ubiquitin ligase that is critical for typical postnatal brain development."
Establishes the initiating molecular lesion.
Neuron-specific paternal UBE3A silencing
In neurons, the paternal UBE3A allele is silenced by imprinting, so maternal disruption leads to loss of effective neuronal UBE3A expression.
neuron link
UBE3A link
nervous system link
Show evidence (1 reference)
PMID:33543479 SUPPORT Other
"in neurons only the maternally inherited UBE3A gene is expressed."
Supports neuron-specific imprinting mechanism.
Reduced neuronal UBE3A protein abundance
Loss of UBE3A protein in neurons reduces E3-ligase-dependent control of protein turnover signaling.
neuron link
brain link
Show evidence (2 references)
PMID:33543479 SUPPORT Other
"Angelman syndrome is caused by the loss of UBE3A protein."
Supports this discrete protein-abundance event.
PMID:40671377 SUPPORT In Vitro
"AS arises due to the neuronal loss of UBE3A, an E3 ligase that regulates protein abundance through the addition of lysine 48 (K48)-linked polyubiquitin chains to proteins targeted for degradation by the ubiquitin proteasome system (UPS)."
Human iPSC-derived cortical-neuron study provides direct molecular support linking neuronal UBE3A loss to altered ubiquitin-dependent protein regulation.
Decreased UBE3A-mediated protein ubiquitination
UBE3A-dependent ubiquitination signaling is reduced, with downstream dysregulation of protein-stability control.
neuron link
protein ubiquitination link ↓ DECREASED regulation of protein stability link ↕ DYSREGULATED
brain link
Show evidence (2 references)
PMID:33543479 SUPPORT Other
"Loss of UBE3A affects multiple signalling pathways in the brain."
Supports broad neuronal signaling dysregulation downstream of reduced ubiquitination control.
PMID:40671377 SUPPORT In Vitro
"We provide evidence UBE3A polyubiquitinates PACSIN1 and GRIPAP1 to regulate protein turnover, with potential implications for impaired activity-dependent synaptic plasticity observed in AS."
Adds direct mechanistic evidence that UBE3A-dependent ubiquitination regulates neuronal protein turnover linked to synaptic dysfunction.
Dysregulated neuronal signaling pathways
Multiple brain signaling pathways become dysregulated rather than a single isolated pathway defect.
neuron link
brain link
Show evidence (1 reference)
PMID:33543479 SUPPORT Other
"given the multitude of signalling mechanisms that are derailed, it is unlikely that targeting a single pathway is going to be very effective."
Supports multipathway dysregulation framing.
Impaired experience-dependent synaptic remodeling
UBE3A-related network pathology impairs synaptic organization and remodeling in neuronal circuits.
neuron link
synapse organization link ↕ DYSREGULATED
cerebral cortex link
Show evidence (3 references)
PMID:24876791 SUPPORT Model Organism
"Studies of mouse models of AS have implicated UBE3A in experience-dependent synaptic remodeling."
Supports this discrete synaptic-remodeling event.
PMID:36237484 SUPPORT Model Organism
"Like in male AS mice, long-term potentiation (LTP) was significantly reduced while long-term depression (LTD) was enhanced at hippocampal CA3-CA1 synapses of female AS mice, as compared to female WT mice."
Provides synapse-level electrophysiologic evidence for impaired plasticity in Angelman model systems.
PMID:40310720 SUPPORT Model Organism
"Moreover, deficits in mEPSC frequency and spike-timing-dependent long-term potentiation, as well as certain behaviors including cognitive inflexibility found in AS mice, are rescued when bred with Kv4.2 conditional knockout mice."
Supports causal linkage between UBE3A downstream signaling defects and synaptic plasticity abnormalities.
Disrupted neuronal excitability homeostasis
Neuronal excitatory/inhibitory balance and electrophysiologic homeostasis are disrupted in cortical networks.
neuron link
modulation of chemical synaptic transmission link ↕ DYSREGULATED regulation of membrane potential link ↕ DYSREGULATED
cerebral cortex link
Show evidence (2 references)
PMID:33543479 SUPPORT Other
"It has been consistently shown that mouse models of Angelman syndrome show marked changes in synaptic plasticity and excitatory/inhibitory balance."
Supports disrupted excitability homeostasis event.
PMID:39914145 SUPPORT Model Organism
"The axon initial segment (AIS) is a critical regulator of neuronal excitability and the initiation site of action potentials."
Adds direct mechanistic support for excitability-homeostasis framing in cortical neurons.
Cortical network hyperexcitability with abnormal EEG background
Hyperexcitable cortical networks produce persistent epileptiform liability and abnormal electroencephalographic backgrounds.
neuron link
cerebral cortex link
Show evidence (1 reference)
PMID:14510623 SUPPORT Human Clinical
"Seizures, abnormal electroencephalography, microcephaly, and scoliosis are observed in >80% of patients."
Supports coupling of epileptic burden with abnormal EEG background.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Angelman Syndrome Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

12
Digestive 2
Constipation VERY_FREQUENT Constipation (HP:0002019)
Show evidence (1 reference)
PMID:28816003 SUPPORT Human Clinical
"The majority of patients' medical records indicated at least one symptom of gastrointestinal dysfunction, with constipation and gastroesophageal reflux disease (GERD) the most common."
Supports constipation as one of the most prevalent GI comorbidities.
Gastroesophageal reflux FREQUENT Gastroesophageal reflux (HP:0002020)
Show evidence (1 reference)
PMID:28816003 SUPPORT Human Clinical
"The majority of patients' medical records indicated at least one symptom of gastrointestinal dysfunction, with constipation and gastroesophageal reflux disease (GERD) the most common."
Supports GERD as a major GI phenotype in AS.
Head and Neck 1
Microcephaly VERY_FREQUENT Microcephaly (HP:0000252)
Show evidence (1 reference)
PMID:14510623 SUPPORT Human Clinical
"Seizures, abnormal electroencephalography, microcephaly, and scoliosis are observed in >80% of patients."
Supports very high prevalence of microcephaly.
Musculoskeletal 1
Scoliosis VERY_FREQUENT Scoliosis (HP:0002650)
Show evidence (1 reference)
PMID:14510623 SUPPORT Human Clinical
"Seizures, abnormal electroencephalography, microcephaly, and scoliosis are observed in >80% of patients."
Supports scoliosis as a common and clinically relevant musculoskeletal manifestation.
Nervous System 8
Severe intellectual disability VERY_FREQUENT Severe intellectual disability (HP:0010864)
Show evidence (1 reference)
PMID:20301323 SUPPORT Human Clinical
"Angelman syndrome (AS) is characterized by severe developmental delay or intellectual disability"
Supports severe cognitive impairment as a core phenotype.
Global developmental delay VERY_FREQUENT Global developmental delay (HP:0001263)
Show evidence (1 reference)
PMID:14510623 SUPPORT Human Clinical
"Clinical findings present in all patients include developmental delay, which becomes apparent by 6-12 months of age"
Supports near-universal developmental delay and its timing.
Severe speech impairment VERY_FREQUENT Poor speech (HP:0002465)
Show evidence (1 reference)
PMID:14510623 SUPPORT Human Clinical
"Clinical findings present in all patients include developmental delay, which becomes apparent by 6-12 months of age, severely impaired expressive language"
Supports severe expressive language impairment as a defining feature.
Gait ataxia VERY_FREQUENT Gait ataxia (HP:0002066)
Show evidence (1 reference)
PMID:20301323 SUPPORT Human Clinical
"Angelman syndrome (AS) is characterized by severe developmental delay or intellectual disability, severe speech impairment, gait ataxia and/or tremulousness of the limbs"
Supports ataxic gait as a cardinal motor phenotype.
Seizures VERY_FREQUENT Seizure (HP:0001250)
Show evidence (1 reference)
PMID:20398390 SUPPORT Human Clinical
"Epilepsy, often severe and hard to control, is present in 85% of patients within the first three years of life, although less than 25% develop seizures during the first year."
Quantifies high seizure prevalence and early onset.
Sleep disturbance FREQUENT Sleep disturbance (HP:0002360)
Show evidence (1 reference)
PMID:24876791 SUPPORT Human Clinical
"The behavioral features of AS include a happy demeanor, easily provoked laughter, short attention span, hypermotoric behavior, mouthing of objects, sleep disturbance, and an affinity for water."
Supports sleep disturbance as a recurring syndrome feature.
Hyperactivity VERY_FREQUENT Hyperactivity (HP:0000752)
Show evidence (1 reference)
PMID:14510623 SUPPORT Human Clinical
"Clinical findings present in all patients include developmental delay, which becomes apparent by 6-12 months of age, severely impaired expressive language, ataxic gait, tremulousness of limbs, and a typical behavioral profile, including a happy demeanor, hypermotoric behavior, and low attention span."
Supports hypermotor/hyperactive behavioral phenotype.
Inappropriate laughter VERY_FREQUENT Inappropriate laughter (HP:0000748)
Show evidence (1 reference)
PMID:20398390 SUPPORT Human Clinical
"Angelman syndrome (AS) is a neuro-behavioural, genetically determined condition, characterized by ataxic jerky movements, happy sociable disposition and unprovoked bouts of laughter in association with seizures, learning disabilities and language impairment."
Supports characteristic laughter/happy demeanor phenotype.
🧬

Genetic Associations

2
UBE3A (Causative)
Show evidence (1 reference)
PMID:33543479 SUPPORT Other
"Angelman syndrome is caused by mutations affecting the maternally inherited UBE3A gene, which encodes an E3-ubiquitin ligase that is critical for typical postnatal brain development."
Supports UBE3A as the primary disease gene.
15q11.2-q13 maternal deletion and imprinting-region abnormalities (Major molecular classes)
Show evidence (1 reference)
PMID:20301323 SUPPORT Human Clinical
"Analysis of parent-specific DNA methylation imprints in the 15q11.2-q13 chromosome region detects approximately 80% of individuals with AS, including those with a deletion, uniparental disomy, or an imprinting defect"
Supports the major non-sequence molecular mechanisms.
💊

Treatments

7
Combination anti-seizure pharmacotherapy
Action: pharmacotherapy MAXO:0000058
Agent: levetiracetam ↗ lamotrigine ↗ clobazam ↗ valproic acid ↗
Seizure control is frequently achieved with combination anti-seizure medication regimens, with a newer-agent-forward approach for tolerability.
Target Phenotypes: Seizure ↗
Show evidence (3 references)
PMID:27206232 SUPPORT Human Clinical
"Newer antiepileptic drugs such as levetiracetam, lamotrigine, and clobazam, and to a lesser extent topiramate, appeared to be as effective - if not more so - as valproic acid and clonazepam while offering more favorable side effect profiles."
Supports use of specific newer ASMs with improved tolerability in Angelman syndrome.
PMID:35862628 PARTIAL Other
"Evidence for treating seizures in AS mainly derives from low-quality studies. Levetiracetam and clobazam are the most commonly used ASMs."
Adds review-level context on current ASM usage patterns and evidence limitations.
PMID:20301323 SUPPORT Human Clinical
"Treatment of manifestations: Anti-seizure medication for seizures."
Direct management recommendation for epilepsy in AS.
Low-glycemic-index dietary therapy
Action: dietary intervention MAXO:0000088
Low-glycemic-index dietary intervention is used as an adjunctive non-pharmacologic seizure-management strategy, with mixed efficacy signals but good tolerability.
Target Phenotypes: Seizure ↗ Sleep disturbance ↗
Show evidence (2 references)
PMID:27206232 SUPPORT Human Clinical
"The low glycemic index treatment also provided effective seizure control with minimal side effects."
Supports LGIT as an adjunctive dietary option for seizure control.
PMID:41121232 PARTIAL Human Clinical
"INTERPRETATION: While the LGID was well-tolerated and showed trends toward neurocognitive and seizure improvements, results were not statistically significant."
Adds contemporary prospective evidence showing tolerability with non-significant efficacy trends.
Tonsillectomy with enhanced postoperative monitoring
Action: tonsillectomy MAXO:0001081
Tonsillectomy is used in selected Angelman patients with sleep-disordered breathing or sialorrhea, and should be paired with structured postoperative respiratory, pain, and feeding monitoring.
Target Phenotypes: Sleep apnea ↗ Sialorrhea ↗
Show evidence (2 references)
PMID:40776598 SUPPORT Human Clinical
"Twelve children with Angelman syndrome underwent tonsillectomy: 7 for sleep-disordered breathing, 4 for sialorrhea, and 1 for recurrent tonsillitis."
Supports procedure-level use of tonsillectomy for specific clinical indications in Angelman syndrome.
PMID:40776598 SUPPORT Human Clinical
"Nine (75.0%) children experienced postoperative complications, most frequently pooling of secretions and oxygen desaturations."
Supports need for enhanced perioperative and postoperative monitoring after tonsillectomy.
Physical therapy
Action: physical therapy MAXO:0000011
Physical therapy is used to improve mobility and support motor function.
Target Phenotypes: Gait ataxia ↗
Show evidence (1 reference)
PMID:20301323 SUPPORT Human Clinical
"Physical therapy, occupational therapy, and speech therapy with an emphasis on nonverbal methods of communication, including augmentative communication aids (e.g., picture cards, communication boards) and signing."
Supports standard multidisciplinary rehabilitative care.
Occupational therapy
Action: occupational therapy MAXO:0001351
Occupational therapy supports adaptive daily living and motor planning.
Show evidence (1 reference)
PMID:20301323 SUPPORT Human Clinical
"Physical therapy, occupational therapy, and speech therapy with an emphasis on nonverbal methods of communication, including augmentative communication aids (e.g., picture cards, communication boards) and signing."
Supports occupational therapy as part of standard multidisciplinary care.
Speech therapy and augmentative communication
Action: speech therapy MAXO:0000930
Speech therapy with nonverbal augmentative strategies is recommended due to severe expressive language deficits.
Target Phenotypes: Severe expressive speech impairment ↗
Show evidence (1 reference)
PMID:20301323 SUPPORT Human Clinical
"Physical therapy, occupational therapy, and speech therapy with an emphasis on nonverbal methods of communication, including augmentative communication aids (e.g., picture cards, communication boards) and signing."
Supports speech-language intervention tailored to severe expressive impairment.
Structured management of gastrointestinal comorbidities
Action: supportive care MAXO:0000950
Ongoing management of reflux, feeding, and constipation is recommended.
Target Phenotypes: Constipation ↗ Gastroesophageal reflux ↗
Show evidence (1 reference)
PMID:20301323 SUPPORT Human Clinical
"Routine management of gastroesophageal reflux, feeding difficulties, constipation, and strabismus."
Supports routine GI-focused symptomatic management.
🔀

Differential Diagnoses

3

Conditions with similar clinical presentations that must be differentiated from Angelman Syndrome:

Prader-Willi syndrome MONDO:0008300
Overlapping Features Prader-Willi syndrome shares the same imprinted chromosomal region and is a key laboratory differential during molecular workup.
Show evidence (1 reference)
PMID:31235867 SUPPORT Human Clinical
"This article is an update of the best practice guidelines for the molecular analysis of Prader-Willi and Angelman syndromes"
Supports direct diagnostic differentiation at the molecular testing level.
HERC2-related Angelman-like neurodevelopmental disorder Not Yet Curated MONDO:0014224
Overlapping Features HERC2-related disorders can mimic major Angelman features and should be considered in Angelman-like presentations without canonical molecular causes.
Show evidence (1 reference)
PMID:33543479 SUPPORT Other
"For instance, patients with a HERC2 mutation share many clinical features with those who have Angelman syndrome."
Supports HERC2 disorder as a clinically relevant differential.
Houge-Janssens syndrome MONDO:0957553
Overlapping Features Houge-Janssens syndrome can overlap clinically with Angelman syndrome through early neurodevelopmental delay, severe language involvement, seizure risk, and behavioral phenotypes.
Distinguishing Features
  • Houge-Janssens syndrome is PP2A-subunit related (PPP2R5D, PPP2R1A, PPP2CA, PPP2R5C) rather than UBE3A-imprinting related.
  • Angelman syndrome is diagnosed through 15q11.2-q13 methylation/UBE3A testing, whereas Houge-Janssens diagnosis relies on PP2A-gene variant identification.
Show evidence (1 reference)
PMID:40555839 SUPPORT Human Clinical
"The core features are neurodevelopmental delay, especially concerning language, prolonged hypotonia, high risk of seizures, and behavior problems."
Supports key symptomatic overlap that makes Houge-Janssens syndrome a relevant clinical differential.
📊

Related Datasets

5
Channelopathy pathogenesis in a human neural cell model of Angelman Syndrome geo:GSE120225
RNA-seq dataset from human induced neurons and 3D cortical organoids derived from Angelman patient iPSCs and UBE3A-knockout hESC lines, used to study network hyperexcitability mechanisms.
human BULK RNA SEQ n=6
Conditions: Angelman syndrome iPSC-derived neural model UBE3A-knockout hESC-derived neural model control neural model
Show evidence (1 reference)
GEO:GSE120225 SUPPORT In Vitro
"Here, by utilizing human induced neurons and 3D cortical organoids derived from AS patient iPSCs and CRISPR-Cas9 mediated UBE3A KO hESCs, we uncovered a novel role of UBE3A in suppressing neuronal hyperexcitability via ubiquitin-mediated degradation of BK channels."
Supports relevance for human-cell-model mechanisms linking UBE3A loss to neuronal hyperexcitability.
Differences in transcription in Angelman syndrome and control person iPSC-derived neurons geo:GSE146640
Human iPSC-neuron transcriptome dataset comparing Angelman syndrome and control lines to characterize disease-associated transcriptional changes.
human BULK RNA SEQ n=6
Conditions: Angelman syndrome iPSC-derived neurons control iPSC-derived neurons
Show evidence (1 reference)
GEO:GSE146640 SUPPORT In Vitro
"So we wanted to study differences in the transcriptome in neurons differentiated from iPSCs that were derived from patients with Angleman syndrome and normal controls."
Supports direct disease-vs-control transcriptomic comparison in human neuron-like cells.
Establishing a molecular phenotype for Angelman Syndrome stem cell-derived neurons geo:GSE160747
Human stem-cell neuron RNA-seq dataset spanning isogenic control versus Angelman syndrome neuronal models and antisense-oligonucleotide intervention conditions relevant to UBE3A reinstatement biology.
human BULK RNA SEQ n=36
Conditions: isogenic control and Angelman syndrome pluripotent stem cell-derived neurons UBE3A ASO-treated H9 hESC-derived neurons scramble ASO-treated H9 hESC-derived neurons
Show evidence (1 reference)
GEO:GSE160747 SUPPORT In Vitro
"mRNAseq on (1) isogenic control and Angelman Syndrome pluripotent stem cell-derived neurons or (2) antisense oligonucleotide-treated H9 hESC-derived neurons"
Supports mechanistically relevant transcriptomic profiling in human AS neuronal models and ASO-treated conditions.
UBE3A reinstatement restores behavior and proteome in an Angelman syndrome mouse model of imprinting defects geo:GSE284678
Mouse RNA-seq resource from an imprinting-center Angelman model (mICD/UPD relevant) with UBE3A reinstatement interventions to evaluate rescue of molecular and behavioral phenotypes.
house mouse BULK RNA SEQ n=14
Conditions: mICD Angelman model mice UBE3A reinstatement conditions control mice
PMID:40877933
Show evidence (2 references)
GEO:GSE284678 SUPPORT Model Organism
"mICD mice showed significant reduction in UBE3A protein, bi-allelic expression of Ube3a-ATS and Mkrn3-Snord115 gene cluster, leading to robust AS behavioral deficits and proteome alterations similar to Ube3aKO mice."
Supports utility of this model for transcriptomic interrogation of imprinting-related Angelman pathophysiology.
GEO:GSE284678 SUPPORT Model Organism
"Genetic UBE3A overexpression in mICD mice, mimicking therapeutic strategies that effectively activate the biallelic silenced Ube3a gene, resulted in a complete rescue of all behavioral and proteome alterations."
Adds mechanistic rescue context relevant to disease-modifying therapy modeling.
Differential Gene Expression in Angelman syndrome deletion vs. int dup(15) Human Lymphocytes geo:GSE32563
Human peripheral-blood microarray dataset comparing Angelman deletion cases and reciprocal 15q duplication cases to identify shared and divergent transcriptional signatures.
human MICROARRAY n=6
Conditions: Angelman syndrome deletion interstitial duplication 15q autism
Show evidence (1 reference)
GEO:GSE32563 SUPPORT Human Clinical
"Microarray analysis revealed 1225 genes that were elevated in AS deletion vs int dup(15) and 976 genes that were elevated in int dup(15) vs AS deletion PBMC (pvalue<0.05)."
Supports this dataset as a human comparative transcriptomic resource connected to UBE3A-region disorders.
🔬

Clinical Trials

3
NCT04428281 PHASE_I COMPLETED
Open-label intrathecal antisense-oligonucleotide trial evaluating RO7248824 safety, tolerability, PK, and PD in participants with Angelman syndrome.
Show evidence (1 reference)
clinicaltrials:NCT04428281 SUPPORT Human Clinical
"This is a phase I, multicenter, non-randomized, adaptive, open-label, multiple ascending, intra-participant, dose-escalation study with a long-term extension (LTE) part and an optional open-label extension (OOE) part."
Supports active clinical development of UBE3A-unsilencing therapy.
NCT04259281 NOT_APPLICABLE COMPLETED
Early-phase intrathecal GTX-102 antisense-oligonucleotide study in pediatric Angelman syndrome.
Show evidence (1 reference)
clinicaltrials:NCT04259281 SUPPORT Human Clinical
"The primary objective of the study is to evaluate the safety and tolerability of multiple-ascending doses of GTX-102 administered by intrathecal (IT) injection to participants with Angelman Syndrome (AS)."
Supports clinical translation of UBE3A-restoration strategies.
NCT04106557 PHASE_III COMPLETED
Randomized placebo-controlled phase III study of oral OV101 (gaboxadol) in pediatric Angelman syndrome.
Target Phenotypes: Sleep disturbance ↗
Show evidence (1 reference)
clinicaltrials:NCT04106557 SUPPORT Human Clinical
"The purpose of this study is to assess the efficacy and safety of oral OV101 (gaboxadol) in pediatric subjects with Angelman syndrome."
Supports late-stage therapeutic evaluation in AS.
{ }

Source YAML

click to show 
name: Angelman Syndrome
creation_date: '2026-03-03T02:33:07Z'
updated_date: '2026-03-05T22:30:44Z'
category: Mendelian
description: >-
  Angelman syndrome is a neurogenetic imprinting disorder caused by deficient
  neuronal expression of the maternally inherited UBE3A allele, with severe
  developmental impairment, minimal speech, gait ataxia, seizures, and a
  characteristic behavioral phenotype.
disease_term:
  preferred_term: Angelman syndrome
  term:
    id: MONDO:0007113
    label: Angelman syndrome
classifications:
  harrisons_chapter:
  - classification_value: hereditary disease
    evidence:
    - reference: PMID:35150089
      reference_title: "A multidisciplinary approach and consensus statement to establish standards of care for Angelman syndrome."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Angelman syndrome (AS) is a rare neurogenetic disorder present in approximately 1/12,000 individuals and characterized by developmental delay, cognitive impairment, motor dysfunction, seizures, gastrointestinal concerns, and abnormal electroencephalographic background."
      explanation: Supports classification as a hereditary genetic disorder.
  - classification_value: nervous system disorder
    evidence:
    - reference: PMID:24876791
      reference_title: "Angelman syndrome: review of clinical and molecular aspects."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: '"Angelman syndrome" (AS) is a neurodevelopmental disorder whose main features are intellectual disability, lack of speech, seizures, and a characteristic behavioral profile.'
      explanation: Supports classification as a nervous system/neurodevelopmental disorder.
definitions:
- name: Clinical syndrome definition
  definition_type: CASE_DEFINITION
  description: >-
    Angelman syndrome is defined clinically by severe developmental delay or
    intellectual disability, severe speech impairment, ataxic movement disorder,
    characteristic happy demeanor, and frequent co-occurrence of seizures and
    microcephaly.
  scope: Core clinical phenotype in pediatric and adult practice
  evidence:
  - reference: PMID:20301323
    reference_title: "Angelman Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Angelman syndrome (AS) is characterized by severe developmental delay or intellectual disability, severe speech impairment, gait ataxia and/or tremulousness of the limbs, and unique behavior with an apparent happy demeanor that includes frequent laughing, smiling, and excitability."
    explanation: Defines the canonical clinical syndrome.
  - reference: PMID:20301323
    reference_title: "Angelman Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Microcephaly and seizures are also common."
    explanation: Adds core neurologic features used in clinical recognition.
- name: Molecular diagnostic criteria framework
  definition_type: DIAGNOSTIC_CRITERIA
  description: >-
    Molecular diagnosis is primarily established by 15q11.2-q13 methylation
    testing with reflex UBE3A sequence analysis when methylation testing is
    negative.
  scope: Molecular confirmation strategy for suspected Angelman syndrome
  evidence:
  - reference: PMID:20301323
    reference_title: "Angelman Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Analysis of parent-specific DNA methylation imprints in the 15q11.2-q13 chromosome region detects approximately 80% of individuals with AS, including those with a deletion, uniparental disomy, or an imprinting defect; fewer than 1% of individuals have a cytogenetically visible chromosome rearrangement (e.g., translocation or inversion)."
    explanation: Supports methylation analysis as first-line molecular testing.
  - reference: PMID:20301323
    reference_title: "Angelman Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "UBE3A sequence analysis detects pathogenic variants in an additional approximately 11% of individuals."
    explanation: Supports second-tier sequencing for methylation-negative cases.
parents:
- Neurodevelopmental disorder
- Imprinting disorder
synonyms:
- AS
- Angelman's syndrome
- happy puppet syndrome (deprecated)
has_subtypes:
- name: Maternal 15q11.2-q13 deletion Angelman syndrome
  classification: molecular
  subtype_frequency: 70%
  description: >-
    Most common molecular subtype, caused by de novo deletion of the maternally
    inherited 15q11.2-q13 region including UBE3A.
  evidence:
  - reference: PMID:14510623
    reference_title: "Angelman syndrome: etiology, clinical features, diagnosis, and management of symptoms."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Approximately 70% of patients show a deletion involving the maternally inherited chromosome 15q11-q13, encompassing a cluster of gamma-aminobutyric acid receptor subunit genes"
    explanation: Quantifies and defines the major deletion subtype.
- name: UBE3A pathogenic variant Angelman syndrome
  classification: molecular
  subtype_frequency: 6-11%
  description: >-
    Subtype caused by pathogenic variants in maternally inherited UBE3A.
  genes:
  - preferred_term: UBE3A
    term:
      id: hgnc:12496
      label: UBE3A
  evidence:
  - reference: PMID:14510623
    reference_title: "Angelman syndrome: etiology, clinical features, diagnosis, and management of symptoms."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "6% harbor intragenic mutations of the ubiquitin-protein ligase E3A (UBE3A) gene."
    explanation: Supports a distinct UBE3A-variant molecular subtype.
  - reference: PMID:20301323
    reference_title: "Angelman Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "UBE3A sequence analysis detects pathogenic variants in an additional approximately 11% of individuals."
    explanation: Provides an additional estimate from a contemporary GeneReviews summary.
- name: Paternal uniparental disomy 15 Angelman syndrome
  classification: molecular
  subtype_frequency: 3%
  description: >-
    Subtype caused by paternal uniparental disomy of chromosome 15 with absent
    functional maternal UBE3A contribution in neurons.
  evidence:
  - reference: PMID:14510623
    reference_title: "Angelman syndrome: etiology, clinical features, diagnosis, and management of symptoms."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "3% show chromosome 15 paternal uniparental disomy (UPD)"
    explanation: Supports UPD as a recognized molecular subtype.
- name: Imprinting defect Angelman syndrome
  classification: molecular
  subtype_frequency: 1%
  description: >-
    Subtype caused by imprinting center defects disrupting maternal-expression
    pattern at the 15q11.2-q13 locus.
  evidence:
  - reference: PMID:14510623
    reference_title: "Angelman syndrome: etiology, clinical features, diagnosis, and management of symptoms."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "1% harbor a mutation in the imprinting center (a transcriptional regulatory element)"
    explanation: Supports imprinting-center defects as a rarer molecular subtype.
inheritance:
- name: Autosomal dominant inheritance with maternal imprinting
  inheritance_term:
    preferred_term: Autosomal dominant inheritance with maternal imprinting
    term:
      id: HP:0012275
      label: Autosomal dominant inheritance with maternal imprinting
  penetrance: COMPLETE
  description: >-
    Disease expression requires loss of the maternally inherited functional UBE3A
    allele in neurons; most cases are simplex/de novo.
  evidence:
  - reference: PMID:20301323
    reference_title: "Angelman Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Individuals with AS typically represent simplex cases (i.e., a single affected family member) and have the disorder as the result of a de novo genetic alteration associated with a very low recurrence risk."
    explanation: Supports predominant de novo occurrence in clinical practice.
  - reference: PMID:20301323
    reference_title: "Angelman Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Less commonly, an individual with AS has the disorder as the result of a genetic alteration associated with an imprinting pattern of autosomal dominant inheritance or variable recurrence risk."
    explanation: Supports the imprinting-associated autosomal dominant inheritance mechanism.
prevalence:
- population: Global
  notes: Birth incidence is consistently reported in the rare-disease range.
  evidence:
  - reference: PMID:35150089
    reference_title: "A multidisciplinary approach and consensus statement to establish standards of care for Angelman syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Angelman syndrome (AS) is a rare neurogenetic disorder present in approximately 1/12,000 individuals"
    explanation: Supports a contemporary prevalence estimate.
  - reference: PMID:25428759
    reference_title: "Angelman syndrome in adulthood."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "AS has an estimated incidence of approximately 1 in 12,000-20,000 live births, but life expectancy by epidemiologic measures remains unknown"
    explanation: Adds an incidence range used in natural-history literature.
progression:
- phase: Early infancy developmental divergence
  age_range: ~6-12 months
  notes: Developmental delay becomes clinically recognizable in late infancy.
  evidence:
  - reference: PMID:20301323
    reference_title: "Angelman Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Developmental delays are first noted at around age six months; however, the unique clinical features of AS do not become manifest until after age one year."
    explanation: Defines early timing of symptom emergence.
  - reference: PMID:14510623
    reference_title: "Angelman syndrome: etiology, clinical features, diagnosis, and management of symptoms."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Clinical findings present in all patients include developmental delay, which becomes apparent by 6-12 months of age"
    explanation: Independent support for infancy-onset developmental divergence.
- phase: Early childhood seizure onset
  age_range: first 3 years
  notes: Epilepsy usually appears in early childhood, with lower frequency in the first year.
  evidence:
  - reference: PMID:20398390
    reference_title: "Epilepsy in patients with Angelman syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Epilepsy, often severe and hard to control, is present in 85% of patients within the first three years of life, although less than 25% develop seizures during the first year."
    explanation: Supports timing and burden of early epilepsy.
- phase: Adolescent/adult neurologic trajectory
  notes: >-
    Seizure burden often improves after childhood but can recur in adulthood;
    sleep dysfunction remains prevalent over the life course.
  evidence:
  - reference: PMID:25428759
    reference_title: "Angelman syndrome in adulthood."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The results of this study indicate that epilepsy severity may assume a bimodal age distribution: seizures are typically most severe in early childhood but may recur in adulthood."
    explanation: Supports age-dependent progression and recurrence pattern.
  - reference: PMID:25428759
    reference_title: "Angelman syndrome in adulthood."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "While late-adolescent and adult sleep patterns were improved when compared to the degree of sleep dysfunction present during infancy and childhood, the prevalence of poor sleep in adults remained quite high."
    explanation: Supports persistence of sleep-related morbidity into adulthood.
pathophysiology:
- name: Maternal UBE3A allele disruption
  description: >-
    Angelman syndrome is initiated by disruption of the maternally inherited
    UBE3A allele (deletion, pathogenic variant, UPD context, or imprinting
    defect).
  genes:
  - preferred_term: UBE3A
    term:
      id: hgnc:12496
      label: UBE3A
  cell_types:
  - preferred_term: neuron
    term:
      id: CL:0000540
      label: neuron
  locations:
  - preferred_term: nervous system
    term:
      id: UBERON:0001016
      label: nervous system
  downstream:
  - target: Neuron-specific paternal UBE3A silencing
    description: Neuronal imprinting limits compensatory expression from the paternal allele.
    evidence:
    - reference: PMID:24876791
      reference_title: "Angelman syndrome: review of clinical and molecular aspects."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "AS is due to deficient expression of the ubiquitin protein ligase E3A (UBE3A) gene, which displays paternal imprinting."
      explanation: Links maternal UBE3A disruption with imprinting-dependent inability to compensate.
  evidence:
  - reference: PMID:33543479
    reference_title: "UBE3A reinstatement as a disease-modifying therapy for Angelman syndrome."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Angelman syndrome is caused by mutations affecting the maternally inherited UBE3A gene, which encodes an E3-ubiquitin ligase that is critical for typical postnatal brain development."
    explanation: Establishes the initiating molecular lesion.
- name: Neuron-specific paternal UBE3A silencing
  description: >-
    In neurons, the paternal UBE3A allele is silenced by imprinting, so maternal
    disruption leads to loss of effective neuronal UBE3A expression.
  genes:
  - preferred_term: UBE3A
    term:
      id: hgnc:12496
      label: UBE3A
  cell_types:
  - preferred_term: neuron
    term:
      id: CL:0000540
      label: neuron
  locations:
  - preferred_term: nervous system
    term:
      id: UBERON:0001016
      label: nervous system
  downstream:
  - target: Reduced neuronal UBE3A protein abundance
    description: Effective neuronal UBE3A protein dosage falls below physiologic levels.
    evidence:
    - reference: PMID:33543479
      reference_title: "UBE3A reinstatement as a disease-modifying therapy for Angelman syndrome."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "Angelman syndrome is caused by the loss of UBE3A protein."
      explanation: Supports direct protein-level consequence of imprinting plus maternal disruption.
  evidence:
  - reference: PMID:33543479
    reference_title: "UBE3A reinstatement as a disease-modifying therapy for Angelman syndrome."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "in neurons only the maternally inherited UBE3A gene is expressed."
    explanation: Supports neuron-specific imprinting mechanism.
- name: Reduced neuronal UBE3A protein abundance
  description: >-
    Loss of UBE3A protein in neurons reduces E3-ligase-dependent control of
    protein turnover signaling.
  cell_types:
  - preferred_term: neuron
    term:
      id: CL:0000540
      label: neuron
  locations:
  - preferred_term: brain
    term:
      id: UBERON:0000955
      label: brain
  downstream:
  - target: Decreased UBE3A-mediated protein ubiquitination
    description: Lower UBE3A dosage reduces normal ubiquitination activity in neuronal systems.
    evidence:
    - reference: PMID:33543479
      reference_title: "UBE3A reinstatement as a disease-modifying therapy for Angelman syndrome."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "Angelman syndrome is caused by mutations affecting the maternally inherited UBE3A gene, which encodes an E3-ubiquitin ligase that is critical for typical postnatal brain development."
      explanation: Supports causal transition from reduced UBE3A protein to decreased E3 ligase function.
  evidence:
  - reference: PMID:33543479
    reference_title: "UBE3A reinstatement as a disease-modifying therapy for Angelman syndrome."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Angelman syndrome is caused by the loss of UBE3A protein."
    explanation: Supports this discrete protein-abundance event.
  - reference: PMID:40671377
    reference_title: "The Ubiquitin E3 Ligase UBE3A Regulates GRIPAP1 and PACSIN1 Proteins Linked to the Endocytic Recycling of AMPA Receptors."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "AS arises due to the neuronal loss of UBE3A, an E3 ligase that regulates protein abundance through the addition of lysine 48 (K48)-linked polyubiquitin chains to proteins targeted for degradation by the ubiquitin proteasome system (UPS)."
    explanation: Human iPSC-derived cortical-neuron study provides direct molecular support linking neuronal UBE3A loss to altered ubiquitin-dependent protein regulation.
- name: Decreased UBE3A-mediated protein ubiquitination
  description: >-
    UBE3A-dependent ubiquitination signaling is reduced, with downstream
    dysregulation of protein-stability control.
  biological_processes:
  - preferred_term: protein ubiquitination
    modifier: DECREASED
    term:
      id: GO:0016567
      label: protein ubiquitination
  - preferred_term: regulation of protein stability
    modifier: DYSREGULATED
    term:
      id: GO:0031647
      label: regulation of protein stability
  cell_types:
  - preferred_term: neuron
    term:
      id: CL:0000540
      label: neuron
  locations:
  - preferred_term: brain
    term:
      id: UBERON:0000955
      label: brain
  downstream:
  - target: Dysregulated neuronal signaling pathways
    description: Loss of ubiquitination control contributes to broad pathway-level signaling derangement.
    evidence:
    - reference: PMID:33543479
      reference_title: "UBE3A reinstatement as a disease-modifying therapy for Angelman syndrome."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "Loss of UBE3A affects multiple signalling pathways in the brain."
      explanation: Supports pathway-level consequences of UBE3A-dependent signaling loss.
    - reference: PMID:40310720
      reference_title: "Activity-dependent degradation of Kv4.2 contributes to synaptic plasticity and behavior in Angelman syndrome model mice."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "Here, we show the voltage-gated K+ channel Kv4.2 as an activity-dependent substrate for UBE3A."
      explanation: Mouse-model evidence supports a specific downstream UBE3A signaling substrate contributing to pathway dysregulation.
  evidence:
  - reference: PMID:33543479
    reference_title: "UBE3A reinstatement as a disease-modifying therapy for Angelman syndrome."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Loss of UBE3A affects multiple signalling pathways in the brain."
    explanation: Supports broad neuronal signaling dysregulation downstream of reduced ubiquitination control.
  - reference: PMID:40671377
    reference_title: "The Ubiquitin E3 Ligase UBE3A Regulates GRIPAP1 and PACSIN1 Proteins Linked to the Endocytic Recycling of AMPA Receptors."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "We provide evidence UBE3A polyubiquitinates PACSIN1 and GRIPAP1 to regulate protein turnover, with potential implications for impaired activity-dependent synaptic plasticity observed in AS."
    explanation: Adds direct mechanistic evidence that UBE3A-dependent ubiquitination regulates neuronal protein turnover linked to synaptic dysfunction.
- name: Dysregulated neuronal signaling pathways
  description: >-
    Multiple brain signaling pathways become dysregulated rather than a single
    isolated pathway defect.
  cell_types:
  - preferred_term: neuron
    term:
      id: CL:0000540
      label: neuron
  locations:
  - preferred_term: brain
    term:
      id: UBERON:0000955
      label: brain
  downstream:
  - target: Impaired experience-dependent synaptic remodeling
    description: Broad pathway dysregulation contributes to synaptic plasticity and remodeling defects.
    evidence:
    - reference: PMID:24876791
      reference_title: "Angelman syndrome: review of clinical and molecular aspects."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "Studies of mouse models of AS have implicated UBE3A in experience-dependent synaptic remodeling."
      explanation: Supports causal transition from pathway dysregulation to impaired synaptic remodeling.
  evidence:
  - reference: PMID:33543479
    reference_title: "UBE3A reinstatement as a disease-modifying therapy for Angelman syndrome."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "given the multitude of signalling mechanisms that are derailed, it is unlikely that targeting a single pathway is going to be very effective."
    explanation: Supports multipathway dysregulation framing.
- name: Impaired experience-dependent synaptic remodeling
  description: >-
    UBE3A-related network pathology impairs synaptic organization and remodeling
    in neuronal circuits.
  cell_types:
  - preferred_term: neuron
    term:
      id: CL:0000540
      label: neuron
  locations:
  - preferred_term: cerebral cortex
    term:
      id: UBERON:0000956
      label: cerebral cortex
  biological_processes:
  - preferred_term: synapse organization
    modifier: DYSREGULATED
    term:
      id: GO:0050808
      label: synapse organization
  downstream:
  - target: Disrupted neuronal excitability homeostasis
    description: Synaptic remodeling defects alter network excitability and transmission balance.
    evidence:
    - reference: PMID:33543479
      reference_title: "UBE3A reinstatement as a disease-modifying therapy for Angelman syndrome."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "It has been consistently shown that mouse models of Angelman syndrome show marked changes in synaptic plasticity and excitatory/inhibitory balance."
      explanation: Supports progression from synaptic remodeling defects to altered excitability balance.
  - target: Severe intellectual disability
    description: Synaptic remodeling dysfunction contributes to severe cognitive impairment.
    evidence:
    - reference: PMID:20301323
      reference_title: "Angelman Syndrome."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Angelman syndrome (AS) is characterized by severe developmental delay or intellectual disability, severe speech impairment"
      explanation: Supports downstream neurodevelopmental cognitive outcome.
  - target: Severe speech impairment
    description: Synaptic-network disruption contributes to profound expressive language deficits.
    evidence:
    - reference: PMID:20301323
      reference_title: "Angelman Syndrome."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Angelman syndrome (AS) is characterized by severe developmental delay or intellectual disability, severe speech impairment"
      explanation: Supports downstream language phenotype.
  - target: Gait ataxia
    description: Network-level motor-circuit dysfunction contributes to persistent gait ataxia.
    evidence:
    - reference: PMID:20301323
      reference_title: "Angelman Syndrome."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Angelman syndrome (AS) is characterized by severe developmental delay or intellectual disability, severe speech impairment, gait ataxia and/or tremulousness of the limbs"
      explanation: Supports downstream motor phenotype.
  evidence:
  - reference: PMID:24876791
    reference_title: "Angelman syndrome: review of clinical and molecular aspects."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Studies of mouse models of AS have implicated UBE3A in experience-dependent synaptic remodeling."
    explanation: Supports this discrete synaptic-remodeling event.
  - reference: PMID:36237484
    reference_title: "Lack of UBE3A-Mediated Regulation of Synaptic SK2 Channels Contributes to Learning and Memory Impairment in the Female Mouse Model of Angelman Syndrome."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Like in male AS mice, long-term potentiation (LTP) was significantly reduced while long-term depression (LTD) was enhanced at hippocampal CA3-CA1 synapses of female AS mice, as compared to female WT mice."
    explanation: Provides synapse-level electrophysiologic evidence for impaired plasticity in Angelman model systems.
  - reference: PMID:40310720
    reference_title: "Activity-dependent degradation of Kv4.2 contributes to synaptic plasticity and behavior in Angelman syndrome model mice."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Moreover, deficits in mEPSC frequency and spike-timing-dependent long-term potentiation, as well as certain behaviors including cognitive inflexibility found in AS mice, are rescued when bred with Kv4.2 conditional knockout mice."
    explanation: Supports causal linkage between UBE3A downstream signaling defects and synaptic plasticity abnormalities.
- name: Disrupted neuronal excitability homeostasis
  description: >-
    Neuronal excitatory/inhibitory balance and electrophysiologic homeostasis are
    disrupted in cortical networks.
  cell_types:
  - preferred_term: neuron
    term:
      id: CL:0000540
      label: neuron
  locations:
  - preferred_term: cerebral cortex
    term:
      id: UBERON:0000956
      label: cerebral cortex
  biological_processes:
  - preferred_term: modulation of chemical synaptic transmission
    modifier: DYSREGULATED
    term:
      id: GO:0050804
      label: modulation of chemical synaptic transmission
  - preferred_term: regulation of membrane potential
    modifier: DYSREGULATED
    term:
      id: GO:0042391
      label: regulation of membrane potential
  downstream:
  - target: Cortical network hyperexcitability with abnormal EEG background
    description: Physiologic instability at synaptic and membrane levels manifests as hyperexcitable cortical activity.
    evidence:
    - reference: PMID:14510623
      reference_title: "Angelman syndrome: etiology, clinical features, diagnosis, and management of symptoms."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Seizures, abnormal electroencephalography, microcephaly, and scoliosis are observed in >80% of patients."
      explanation: Supports transition from excitability dysregulation to abnormal EEG-related network state.
    - reference: PMID:39914145
      reference_title: "UBE3A controls axon initial segment in the cortical pyramidal neurons."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "In this study, we compared wild-type mice with three different Ube3a-deficient mice and observed specific elongation of the AIS in the prelimbic cortex of the medial prefrontal cortex but not in the somatosensory cortex or motor cortex, as previously reported."
      explanation: Region-specific AIS structural changes in Ube3a-deficient cortex support cortical excitability-network disturbance.
  evidence:
  - reference: PMID:33543479
    reference_title: "UBE3A reinstatement as a disease-modifying therapy for Angelman syndrome."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "It has been consistently shown that mouse models of Angelman syndrome show marked changes in synaptic plasticity and excitatory/inhibitory balance."
    explanation: Supports disrupted excitability homeostasis event.
  - reference: PMID:39914145
    reference_title: "UBE3A controls axon initial segment in the cortical pyramidal neurons."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "The axon initial segment (AIS) is a critical regulator of neuronal excitability and the initiation site of action potentials."
    explanation: Adds direct mechanistic support for excitability-homeostasis framing in cortical neurons.
- name: Cortical network hyperexcitability with abnormal EEG background
  description: >-
    Hyperexcitable cortical networks produce persistent epileptiform liability
    and abnormal electroencephalographic backgrounds.
  cell_types:
  - preferred_term: neuron
    term:
      id: CL:0000540
      label: neuron
  locations:
  - preferred_term: cerebral cortex
    term:
      id: UBERON:0000956
      label: cerebral cortex
  downstream:
  - target: Seizures
    description: Hyperexcitable cortical networks drive recurrent seizure phenotypes.
    evidence:
    - reference: PMID:20398390
      reference_title: "Epilepsy in patients with Angelman syndrome."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Epilepsy, often severe and hard to control, is present in 85% of patients within the first three years of life, although less than 25% develop seizures during the first year."
      explanation: Supports high seizure burden as a downstream clinical manifestation.
  - target: Sleep disturbance
    description: Persistent network instability contributes to long-term sleep dysregulation.
    evidence:
    - reference: PMID:25428759
      reference_title: "Angelman syndrome in adulthood."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "While late-adolescent and adult sleep patterns were improved when compared to the degree of sleep dysfunction present during infancy and childhood, the prevalence of poor sleep in adults remained quite high."
      explanation: Supports persistent sleep dysregulation as a downstream neurophysiologic phenotype.
  evidence:
  - reference: PMID:14510623
    reference_title: "Angelman syndrome: etiology, clinical features, diagnosis, and management of symptoms."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Seizures, abnormal electroencephalography, microcephaly, and scoliosis are observed in >80% of patients."
    explanation: Supports coupling of epileptic burden with abnormal EEG background.
phenotypes:
- name: Severe intellectual disability
  category: Neurodevelopmental
  frequency: VERY_FREQUENT
  diagnostic: true
  phenotype_term:
    preferred_term: Severe intellectual disability
    term:
      id: HP:0010864
      label: Severe intellectual disability
  evidence:
  - reference: PMID:20301323
    reference_title: "Angelman Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Angelman syndrome (AS) is characterized by severe developmental delay or intellectual disability"
    explanation: Supports severe cognitive impairment as a core phenotype.
- name: Global developmental delay
  category: Neurodevelopmental
  frequency: VERY_FREQUENT
  diagnostic: true
  phenotype_term:
    preferred_term: Global developmental delay
    term:
      id: HP:0001263
      label: Global developmental delay
  evidence:
  - reference: PMID:14510623
    reference_title: "Angelman syndrome: etiology, clinical features, diagnosis, and management of symptoms."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Clinical findings present in all patients include developmental delay, which becomes apparent by 6-12 months of age"
    explanation: Supports near-universal developmental delay and its timing.
- name: Severe speech impairment
  category: Neurodevelopmental
  frequency: VERY_FREQUENT
  diagnostic: true
  phenotype_term:
    preferred_term: Severe expressive speech impairment
    term:
      id: HP:0002465
      label: Poor speech
  evidence:
  - reference: PMID:14510623
    reference_title: "Angelman syndrome: etiology, clinical features, diagnosis, and management of symptoms."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Clinical findings present in all patients include developmental delay, which becomes apparent by 6-12 months of age, severely impaired expressive language"
    explanation: Supports severe expressive language impairment as a defining feature.
- name: Gait ataxia
  category: Neurological
  frequency: VERY_FREQUENT
  diagnostic: true
  phenotype_term:
    preferred_term: Gait ataxia
    term:
      id: HP:0002066
      label: Gait ataxia
  evidence:
  - reference: PMID:20301323
    reference_title: "Angelman Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Angelman syndrome (AS) is characterized by severe developmental delay or intellectual disability, severe speech impairment, gait ataxia and/or tremulousness of the limbs"
    explanation: Supports ataxic gait as a cardinal motor phenotype.
- name: Seizures
  category: Neurological
  frequency: VERY_FREQUENT
  diagnostic: true
  phenotype_term:
    preferred_term: Seizure
    term:
      id: HP:0001250
      label: Seizure
  evidence:
  - reference: PMID:20398390
    reference_title: "Epilepsy in patients with Angelman syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Epilepsy, often severe and hard to control, is present in 85% of patients within the first three years of life, although less than 25% develop seizures during the first year."
    explanation: Quantifies high seizure prevalence and early onset.
- name: Sleep disturbance
  category: Neurological
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Sleep disturbance
    term:
      id: HP:0002360
      label: Sleep disturbance
  evidence:
  - reference: PMID:24876791
    reference_title: "Angelman syndrome: review of clinical and molecular aspects."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The behavioral features of AS include a happy demeanor, easily provoked laughter, short attention span, hypermotoric behavior, mouthing of objects, sleep disturbance, and an affinity for water."
    explanation: Supports sleep disturbance as a recurring syndrome feature.
- name: Microcephaly
  category: Neurological
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Microcephaly
    term:
      id: HP:0000252
      label: Microcephaly
  evidence:
  - reference: PMID:14510623
    reference_title: "Angelman syndrome: etiology, clinical features, diagnosis, and management of symptoms."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Seizures, abnormal electroencephalography, microcephaly, and scoliosis are observed in >80% of patients."
    explanation: Supports very high prevalence of microcephaly.
- name: Hyperactivity
  category: Behavioral
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Hyperactivity
    term:
      id: HP:0000752
      label: Hyperactivity
  evidence:
  - reference: PMID:14510623
    reference_title: "Angelman syndrome: etiology, clinical features, diagnosis, and management of symptoms."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Clinical findings present in all patients include developmental delay, which becomes apparent by 6-12 months of age, severely impaired expressive language, ataxic gait, tremulousness of limbs, and a typical behavioral profile, including a happy demeanor, hypermotoric behavior, and low attention span."
    explanation: Supports hypermotor/hyperactive behavioral phenotype.
- name: Inappropriate laughter
  category: Behavioral
  frequency: VERY_FREQUENT
  diagnostic: true
  phenotype_term:
    preferred_term: Inappropriate laughter
    term:
      id: HP:0000748
      label: Inappropriate laughter
  evidence:
  - reference: PMID:20398390
    reference_title: "Epilepsy in patients with Angelman syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Angelman syndrome (AS) is a neuro-behavioural, genetically determined condition, characterized by ataxic jerky movements, happy sociable disposition and unprovoked bouts of laughter in association with seizures, learning disabilities and language impairment."
    explanation: Supports characteristic laughter/happy demeanor phenotype.
- name: Constipation
  category: Gastrointestinal
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Constipation
    term:
      id: HP:0002019
      label: Constipation
  evidence:
  - reference: PMID:28816003
    reference_title: "Prevalence of gastrointestinal symptoms in Angelman syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The majority of patients' medical records indicated at least one symptom of gastrointestinal dysfunction, with constipation and gastroesophageal reflux disease (GERD) the most common."
    explanation: Supports constipation as one of the most prevalent GI comorbidities.
- name: Gastroesophageal reflux
  category: Gastrointestinal
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Gastroesophageal reflux
    term:
      id: HP:0002020
      label: Gastroesophageal reflux
  evidence:
  - reference: PMID:28816003
    reference_title: "Prevalence of gastrointestinal symptoms in Angelman syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The majority of patients' medical records indicated at least one symptom of gastrointestinal dysfunction, with constipation and gastroesophageal reflux disease (GERD) the most common."
    explanation: Supports GERD as a major GI phenotype in AS.
- name: Scoliosis
  category: Musculoskeletal
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Scoliosis
    term:
      id: HP:0002650
      label: Scoliosis
  evidence:
  - reference: PMID:14510623
    reference_title: "Angelman syndrome: etiology, clinical features, diagnosis, and management of symptoms."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Seizures, abnormal electroencephalography, microcephaly, and scoliosis are observed in >80% of patients."
    explanation: Supports scoliosis as a common and clinically relevant musculoskeletal manifestation.
genetic:
- name: UBE3A
  gene_term:
    preferred_term: UBE3A
    term:
      id: hgnc:12496
      label: UBE3A
  association: Causative
  notes: >-
    Loss of maternally inherited UBE3A function in neurons is the central
    genetic mechanism across molecular classes.
  evidence:
  - reference: PMID:33543479
    reference_title: "UBE3A reinstatement as a disease-modifying therapy for Angelman syndrome."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Angelman syndrome is caused by mutations affecting the maternally inherited UBE3A gene, which encodes an E3-ubiquitin ligase that is critical for typical postnatal brain development."
    explanation: Supports UBE3A as the primary disease gene.
- name: 15q11.2-q13 maternal deletion and imprinting-region abnormalities
  association: Major molecular classes
  notes: >-
    Large maternal deletions, paternal UPD, and imprinting defects account for
    most non-UBE3A-variant cases.
  evidence:
  - reference: PMID:20301323
    reference_title: "Angelman Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Analysis of parent-specific DNA methylation imprints in the 15q11.2-q13 chromosome region detects approximately 80% of individuals with AS, including those with a deletion, uniparental disomy, or an imprinting defect"
    explanation: Supports the major non-sequence molecular mechanisms.
diagnosis:
- name: Parent-specific DNA methylation analysis of 15q11.2-q13
  diagnosis_term:
    preferred_term: diagnostic procedure
    term:
      id: MAXO:0000003
      label: diagnostic procedure
  description: First-line molecular test in suspected Angelman syndrome.
  results: Detects most cases due to deletion, UPD, or imprinting defect.
  evidence:
  - reference: PMID:20301323
    reference_title: "Angelman Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Analysis of parent-specific DNA methylation imprints in the 15q11.2-q13 chromosome region detects approximately 80% of individuals with AS, including those with a deletion, uniparental disomy, or an imprinting defect"
    explanation: Supports methylation analysis as primary diagnostic assay.
- name: UBE3A sequence analysis
  diagnosis_term:
    preferred_term: diagnostic procedure
    term:
      id: MAXO:0000003
      label: diagnostic procedure
  description: Reflex molecular testing when methylation study is negative.
  results: Adds diagnostic yield for UBE3A pathogenic variants.
  evidence:
  - reference: PMID:20301323
    reference_title: "Angelman Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "UBE3A sequence analysis detects pathogenic variants in an additional approximately 11% of individuals."
    explanation: Supports reflex sequencing after negative methylation testing.
- name: Consensus clinical diagnostic criteria assessment
  diagnosis_term:
    preferred_term: diagnostic procedure
    term:
      id: MAXO:0000003
      label: diagnostic procedure
  description: Clinical phenotype evaluation remains central, particularly in molecularly unresolved cases.
  evidence:
  - reference: PMID:20301323
    reference_title: "Angelman Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The diagnosis of AS is established in a proband who meets the consensus clinical diagnostic criteria and/or who has findings on molecular genetic testing that suggest deficient expression or function of the maternally inherited UBE3A allele."
    explanation: Supports integrated clinical-plus-molecular diagnosis.
- name: Electroencephalographic supportive testing
  diagnosis_term:
    preferred_term: diagnostic procedure
    term:
      id: MAXO:0000003
      label: diagnostic procedure
  description: EEG abnormalities are supportive but not fully specific.
  evidence:
  - reference: PMID:20398390
    reference_title: "Epilepsy in patients with Angelman syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The EEG abnormalities are not themselves pathognomonic of AS and both background activity and epileptic discharges vary even in the same patient with time."
    explanation: Supports EEG as a supportive, non-pathognomonic diagnostic adjunct.
treatments:
- name: Combination anti-seizure pharmacotherapy
  description: >-
    Seizure control is frequently achieved with combination anti-seizure
    medication regimens, with a newer-agent-forward approach for tolerability.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
    therapeutic_agent:
    - preferred_term: levetiracetam
      term:
        id: CHEBI:6437
        label: levetiracetam
    - preferred_term: lamotrigine
      term:
        id: CHEBI:6367
        label: lamotrigine
    - preferred_term: clobazam
      term:
        id: CHEBI:31413
        label: clobazam
    - preferred_term: valproic acid
      term:
        id: CHEBI:39867
        label: valproic acid
  target_phenotypes:
  - preferred_term: Seizure
    term:
      id: HP:0001250
      label: Seizure
  evidence:
  - reference: PMID:27206232
    reference_title: "Seizure treatment in Angelman syndrome: A case series from the Angelman Syndrome Clinic at Massachusetts General Hospital."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Newer antiepileptic drugs such as levetiracetam, lamotrigine, and clobazam, and to a lesser extent topiramate, appeared to be as effective - if not more so - as valproic acid and clonazepam while offering more favorable side effect profiles."
    explanation: Supports use of specific newer ASMs with improved tolerability in Angelman syndrome.
  - reference: PMID:35862628
    reference_title: "Pharmacotherapeutic management of seizures in patients with Angleman Syndrome."
    supports: PARTIAL
    evidence_source: OTHER
    snippet: "Evidence for treating seizures in AS mainly derives from low-quality studies. Levetiracetam and clobazam are the most commonly used ASMs."
    explanation: Adds review-level context on current ASM usage patterns and evidence limitations.
  - reference: PMID:20301323
    reference_title: "Angelman Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Treatment of manifestations: Anti-seizure medication for seizures."
    explanation: Direct management recommendation for epilepsy in AS.
- name: Low-glycemic-index dietary therapy
  description: >-
    Low-glycemic-index dietary intervention is used as an adjunctive
    non-pharmacologic seizure-management strategy, with mixed efficacy signals
    but good tolerability.
  treatment_term:
    preferred_term: dietary intervention
    term:
      id: MAXO:0000088
      label: dietary intervention
  target_phenotypes:
  - preferred_term: Seizure
    term:
      id: HP:0001250
      label: Seizure
  - preferred_term: Sleep disturbance
    term:
      id: HP:0002360
      label: Sleep disturbance
  evidence:
  - reference: PMID:27206232
    reference_title: "Seizure treatment in Angelman syndrome: A case series from the Angelman Syndrome Clinic at Massachusetts General Hospital."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The low glycemic index treatment also provided effective seizure control with minimal side effects."
    explanation: Supports LGIT as an adjunctive dietary option for seizure control.
  - reference: PMID:41121232
    reference_title: "Efficacy and tolerability of a low-glycemic-index ketogenic diet in Angelman syndrome: findings from the DIANE study."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: "INTERPRETATION: While the LGID was well-tolerated and showed trends toward neurocognitive and seizure improvements, results were not statistically significant."
    explanation: Adds contemporary prospective evidence showing tolerability with non-significant efficacy trends.
- name: Tonsillectomy with enhanced postoperative monitoring
  description: >-
    Tonsillectomy is used in selected Angelman patients with sleep-disordered
    breathing or sialorrhea, and should be paired with structured postoperative
    respiratory, pain, and feeding monitoring.
  treatment_term:
    preferred_term: tonsillectomy
    term:
      id: MAXO:0001081
      label: tonsillectomy
  target_phenotypes:
  - preferred_term: Sleep apnea
    term:
      id: HP:0010535
      label: Sleep apnea
  - preferred_term: Sialorrhea
    term:
      id: HP:0002307
      label: Drooling
  evidence:
  - reference: PMID:40776598
    reference_title: "Outcomes After Tonsillectomy in Children With Angelman Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Twelve children with Angelman syndrome underwent tonsillectomy: 7 for sleep-disordered breathing, 4 for sialorrhea, and 1 for recurrent tonsillitis."
    explanation: Supports procedure-level use of tonsillectomy for specific clinical indications in Angelman syndrome.
  - reference: PMID:40776598
    reference_title: "Outcomes After Tonsillectomy in Children With Angelman Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Nine (75.0%) children experienced postoperative complications, most frequently pooling of secretions and oxygen desaturations."
    explanation: Supports need for enhanced perioperative and postoperative monitoring after tonsillectomy.
- name: Physical therapy
  description: Physical therapy is used to improve mobility and support motor function.
  treatment_term:
    preferred_term: physical therapy
    term:
      id: MAXO:0000011
      label: physical therapy
  target_phenotypes:
  - preferred_term: Gait ataxia
    term:
      id: HP:0002066
      label: Gait ataxia
  evidence:
  - reference: PMID:20301323
    reference_title: "Angelman Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Physical therapy, occupational therapy, and speech therapy with an emphasis on nonverbal methods of communication, including augmentative communication aids (e.g., picture cards, communication boards) and signing."
    explanation: Supports standard multidisciplinary rehabilitative care.
- name: Occupational therapy
  description: Occupational therapy supports adaptive daily living and motor planning.
  treatment_term:
    preferred_term: occupational therapy
    term:
      id: MAXO:0001351
      label: occupational therapy
  evidence:
  - reference: PMID:20301323
    reference_title: "Angelman Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Physical therapy, occupational therapy, and speech therapy with an emphasis on nonverbal methods of communication, including augmentative communication aids (e.g., picture cards, communication boards) and signing."
    explanation: Supports occupational therapy as part of standard multidisciplinary care.
- name: Speech therapy and augmentative communication
  description: Speech therapy with nonverbal augmentative strategies is recommended due to severe expressive language deficits.
  treatment_term:
    preferred_term: speech therapy
    term:
      id: MAXO:0000930
      label: speech therapy
  target_phenotypes:
  - preferred_term: Severe expressive speech impairment
    term:
      id: HP:0002465
      label: Poor speech
  evidence:
  - reference: PMID:20301323
    reference_title: "Angelman Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Physical therapy, occupational therapy, and speech therapy with an emphasis on nonverbal methods of communication, including augmentative communication aids (e.g., picture cards, communication boards) and signing."
    explanation: Supports speech-language intervention tailored to severe expressive impairment.
- name: Structured management of gastrointestinal comorbidities
  description: Ongoing management of reflux, feeding, and constipation is recommended.
  treatment_term:
    preferred_term: supportive care
    term:
      id: MAXO:0000950
      label: supportive care
  target_phenotypes:
  - preferred_term: Constipation
    term:
      id: HP:0002019
      label: Constipation
  - preferred_term: Gastroesophageal reflux
    term:
      id: HP:0002020
      label: Gastroesophageal reflux
  evidence:
  - reference: PMID:20301323
    reference_title: "Angelman Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Routine management of gastroesophageal reflux, feeding difficulties, constipation, and strabismus."
    explanation: Supports routine GI-focused symptomatic management.
differential_diagnoses:
- name: Prader-Willi syndrome
  disease_term:
    preferred_term: Prader-Willi syndrome
    term:
      id: MONDO:0008300
      label: Prader-Willi syndrome
  description: >-
    Prader-Willi syndrome shares the same imprinted chromosomal region and is a
    key laboratory differential during molecular workup.
  evidence:
  - reference: PMID:31235867
    reference_title: "Update of the EMQN/ACGS best practice guidelines for molecular analysis of Prader-Willi and Angelman syndromes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "This article is an update of the best practice guidelines for the molecular analysis of Prader-Willi and Angelman syndromes"
    explanation: Supports direct diagnostic differentiation at the molecular testing level.
- name: HERC2-related Angelman-like neurodevelopmental disorder
  disease_term:
    preferred_term: HERC2-related Angelman-like neurodevelopmental disorder
    term:
      id: MONDO:0014224
      label: developmental delay with autism spectrum disorder and gait instability
  description: >-
    HERC2-related disorders can mimic major Angelman features and should be
    considered in Angelman-like presentations without canonical molecular causes.
  evidence:
  - reference: PMID:33543479
    reference_title: "UBE3A reinstatement as a disease-modifying therapy for Angelman syndrome."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "For instance, patients with a HERC2 mutation share many clinical features with those who have Angelman syndrome."
    explanation: Supports HERC2 disorder as a clinically relevant differential.
- name: Houge-Janssens syndrome
  disease_term:
    preferred_term: Houge-Janssens syndrome
    term:
      id: MONDO:0957553
      label: Houge-Janssens syndrome
  description: >-
    Houge-Janssens syndrome can overlap clinically with Angelman syndrome through
    early neurodevelopmental delay, severe language involvement, seizure risk, and
    behavioral phenotypes.
  distinguishing_features:
  - Houge-Janssens syndrome is PP2A-subunit related (PPP2R5D, PPP2R1A, PPP2CA, PPP2R5C) rather than UBE3A-imprinting related.
  - Angelman syndrome is diagnosed through 15q11.2-q13 methylation/UBE3A testing, whereas Houge-Janssens diagnosis relies on PP2A-gene variant identification.
  evidence:
  - reference: PMID:40555839
    reference_title: "Houge-Janssens syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The core features are neurodevelopmental delay, especially concerning language, prolonged hypotonia, high risk of seizures, and behavior problems."
    explanation: Supports key symptomatic overlap that makes Houge-Janssens syndrome a relevant clinical differential.
datasets:
- accession: geo:GSE120225
  title: Channelopathy pathogenesis in a human neural cell model of Angelman Syndrome
  description: >-
    RNA-seq dataset from human induced neurons and 3D cortical organoids derived
    from Angelman patient iPSCs and UBE3A-knockout hESC lines, used to study
    network hyperexcitability mechanisms.
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  data_type: BULK_RNA_SEQ
  sample_count: 6
  conditions:
  - Angelman syndrome iPSC-derived neural model
  - UBE3A-knockout hESC-derived neural model
  - control neural model
  evidence:
  - reference: GEO:GSE120225
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Here, by utilizing human induced neurons and 3D cortical organoids derived from AS patient iPSCs and CRISPR-Cas9 mediated UBE3A KO hESCs, we uncovered a novel role of UBE3A in suppressing neuronal hyperexcitability via ubiquitin-mediated degradation of BK channels."
    explanation: Supports relevance for human-cell-model mechanisms linking UBE3A loss to neuronal hyperexcitability.
- accession: geo:GSE146640
  title: Differences in transcription in Angelman syndrome and control person iPSC-derived neurons
  description: >-
    Human iPSC-neuron transcriptome dataset comparing Angelman syndrome and
    control lines to characterize disease-associated transcriptional changes.
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  data_type: BULK_RNA_SEQ
  sample_count: 6
  conditions:
  - Angelman syndrome iPSC-derived neurons
  - control iPSC-derived neurons
  evidence:
  - reference: GEO:GSE146640
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "So we wanted to study differences in the transcriptome in neurons differentiated from iPSCs that were derived from patients with Angleman syndrome and normal controls."
    explanation: Supports direct disease-vs-control transcriptomic comparison in human neuron-like cells.
- accession: geo:GSE160747
  title: Establishing a molecular phenotype for Angelman Syndrome stem cell-derived neurons
  description: >-
    Human stem-cell neuron RNA-seq dataset spanning isogenic control versus
    Angelman syndrome neuronal models and antisense-oligonucleotide intervention
    conditions relevant to UBE3A reinstatement biology.
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  data_type: BULK_RNA_SEQ
  sample_count: 36
  conditions:
  - isogenic control and Angelman syndrome pluripotent stem cell-derived neurons
  - UBE3A ASO-treated H9 hESC-derived neurons
  - scramble ASO-treated H9 hESC-derived neurons
  evidence:
  - reference: GEO:GSE160747
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "mRNAseq on (1) isogenic control and Angelman Syndrome pluripotent stem cell-derived neurons or (2) antisense oligonucleotide-treated H9 hESC-derived neurons"
    explanation: Supports mechanistically relevant transcriptomic profiling in human AS neuronal models and ASO-treated conditions.
- accession: geo:GSE284678
  title: UBE3A reinstatement restores behavior and proteome in an Angelman syndrome mouse model of imprinting defects
  description: >-
    Mouse RNA-seq resource from an imprinting-center Angelman model (mICD/UPD
    relevant) with UBE3A reinstatement interventions to evaluate rescue of
    molecular and behavioral phenotypes.
  organism:
    preferred_term: house mouse
    term:
      id: NCBITaxon:10090
      label: Mus musculus
  data_type: BULK_RNA_SEQ
  sample_count: 14
  conditions:
  - mICD Angelman model mice
  - UBE3A reinstatement conditions
  - control mice
  publication: PMID:40877933
  evidence:
  - reference: GEO:GSE284678
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "mICD mice showed significant reduction in UBE3A protein, bi-allelic expression of Ube3a-ATS and Mkrn3-Snord115 gene cluster, leading to robust AS behavioral deficits and proteome alterations similar to Ube3aKO mice."
    explanation: Supports utility of this model for transcriptomic interrogation of imprinting-related Angelman pathophysiology.
  - reference: GEO:GSE284678
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Genetic UBE3A overexpression in mICD mice, mimicking therapeutic strategies that effectively activate the biallelic silenced Ube3a gene, resulted in a complete rescue of all behavioral and proteome alterations."
    explanation: Adds mechanistic rescue context relevant to disease-modifying therapy modeling.
- accession: geo:GSE32563
  title: Differential Gene Expression in Angelman syndrome deletion vs. int dup(15) Human Lymphocytes
  description: >-
    Human peripheral-blood microarray dataset comparing Angelman deletion cases
    and reciprocal 15q duplication cases to identify shared and divergent
    transcriptional signatures.
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  data_type: MICROARRAY
  sample_count: 6
  conditions:
  - Angelman syndrome deletion
  - interstitial duplication 15q autism
  evidence:
  - reference: GEO:GSE32563
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Microarray analysis revealed 1225 genes that were elevated in AS deletion vs int dup(15) and 976 genes that were elevated in int dup(15) vs AS deletion PBMC (pvalue<0.05)."
    explanation: Supports this dataset as a human comparative transcriptomic resource connected to UBE3A-region disorders.
clinical_trials:
- name: NCT04428281
  phase: PHASE_I
  status: COMPLETED
  description: >-
    Open-label intrathecal antisense-oligonucleotide trial evaluating
    RO7248824 safety, tolerability, PK, and PD in participants with Angelman
    syndrome.
  evidence:
  - reference: clinicaltrials:NCT04428281
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "This is a phase I, multicenter, non-randomized, adaptive, open-label, multiple ascending, intra-participant, dose-escalation study with a long-term extension (LTE) part and an optional open-label extension (OOE) part."
    explanation: Supports active clinical development of UBE3A-unsilencing therapy.
- name: NCT04259281
  phase: NOT_APPLICABLE
  status: COMPLETED
  description: >-
    Early-phase intrathecal GTX-102 antisense-oligonucleotide study in
    pediatric Angelman syndrome.
  evidence:
  - reference: clinicaltrials:NCT04259281
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The primary objective of the study is to evaluate the safety and tolerability of multiple-ascending doses of GTX-102 administered by intrathecal (IT) injection to participants with Angelman Syndrome (AS)."
    explanation: Supports clinical translation of UBE3A-restoration strategies.
  notes: Trial title indicates phase 1/2 design; mapped to NOT_APPLICABLE due schema phase granularity.
- name: NCT04106557
  phase: PHASE_III
  status: COMPLETED
  description: >-
    Randomized placebo-controlled phase III study of oral OV101 (gaboxadol) in
    pediatric Angelman syndrome.
  target_phenotypes:
  - preferred_term: Sleep disturbance
    term:
      id: HP:0002360
      label: Sleep disturbance
  evidence:
  - reference: clinicaltrials:NCT04106557
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The purpose of this study is to assess the efficacy and safety of oral OV101 (gaboxadol) in pediatric subjects with Angelman syndrome."
    explanation: Supports late-stage therapeutic evaluation in AS.
notes: >-
  Contemporary consensus guidance emphasizes standardized multidisciplinary care
  as a prerequisite for evaluating emerging disease-modifying therapies in
  Angelman syndrome.